Aim: To compare the efficacy of indapamide (1.25 mg daily) and low-salt diet (<100 mmol/day) separately and in combination in essential hypertensive patients with inadequate BP response to perindopril.

Design And Methods: Randomized double-blind, double-dummy, crossover design. The randomized treatments were indapamide 1.25 mg daily, sodium chloride 80 mmol daily, the combination of indapamide and sodium chloride and placebo. All patients received perindopril 4 mg daily and maintained a low-sodium diet.

Results: 19 patients entered and 17 completed the study. Prior to randomization, average clinic sitting blood pressure was 162/101 mm Hg and average 24-h urine sodium excretion was 157 mmol/day. Compared to the phase in which patients received perindopril with sodium repletion, clinic and ambulatory BPs were significantly reduced (p<0.01) in all the other phases. Indapamide had a greater effect on BP than dietary sodium restriction, and in combination their effects were additive. The effect of indapamide on ambulatory BP persisted throughout 24 h, but the effect of the low-salt diet was predominantly observed during waking hours.

Conclusions: In hypertensives with BP resistant to the angiotensin converting enzyme (ACE) inhibitor perindopril, the diuretic indapamide had greater additional efficacy and longer duration of action than dietary sodium restriction. In combination they had additive effects on BP.

Download full-text PDF

Source
http://dx.doi.org/10.1080/080370598437169DOI Listing

Publication Analysis

Top Keywords

low-dose diuretic
4
diuretic and/or
4
and/or dietary
4
dietary sodium
4
sodium restriction
4
restriction blood
4
blood pressure
4
pressure resistant
4
resistant ace
4
ace inhibitor
4

Similar Publications

Radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged as a sensitive tool for PET imaging of prostate cancer (PCa) recurrence. Yet urinary bladder activity may obscure the visualization of prostate bed recurrence. Among the Food and Drug Administration-approved PSMA radiopharmaceuticals, F-flotufolastat (rhPSMA-7.

View Article and Find Full Text PDF

Rationale: Chylothorax is a rare adverse effect that is associated with dasatinib, a tyrosine kinase inhibitor administered for chronic myeloid leukemia (CML) treatment. Most reported cases have described standard dosing. In this case report, we described a 43-year-old male patient with CML who developed chylothorax after 4 years of low-dose dasatinib therapy.

View Article and Find Full Text PDF

[A commentary: New carbonic anhydrase IX-targeted probes for imaging hypoxic tumors].

Bull Cancer

February 2025

Département de biologie expérimentale des tumeurs, institut de carcinogenèse, centre national de recherche médicale en oncologie N.N. Blokhin, ministère de la Santé de Russie, 24 Kashirskoe shosse, Moscou 115522, Fédération de Russie. Electronic address:

In 2023, the journals "Bioconjugate Chemistry" and "Sensors and Actuators B: Chemical" published two papers describing new biosensors for imaging hypoxic regions in tumors. Cao et al. combined acetazolamide (AZA) to target carbonic anhydrase IX (CA IX) with two tyrosine-derived Mn(II)-ethylenediaminetetraacetic acid chelates (TyEDTA) on a rigid triazine (TA) scaffold.

View Article and Find Full Text PDF

Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation.

Med

December 2024

Masira Research Institute, Universidad de Santander (UDES), Bucaramanga, Colombia; Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador. Electronic address:

The GMRx2 trial in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control.

View Article and Find Full Text PDF

Autonomous cortisol secretion promotes vascular calcification in vivo and in vitro under hyperaldosteronism.

Hypertens Res

January 2025

Department of Business Administration and Graduate School of Service Management, Chihlee University of Technology, New Taipei City, Taiwan, ROC.

Article Synopsis
  • Autonomous cortisol secretion (ACS) is often found in primary aldosteronism (PA) patients, but its impact on cardiovascular health, particularly vascular calcification, is not well understood.
  • In a study of 339 PA patients, those with ACS had significantly higher abdominal aortic calcification (AAC) scores compared to those without ACS, indicating a stronger cardiovascular burden.
  • The research also shows that cortisol enhances vascular calcification in the presence of high aldosterone levels through a mineralocorticoid receptor mechanism, which can be blocked by the drug eplerenone.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!